Investıgatıon of the Effects of Favipiravir and Oseltamivir Active Substances Used in the Treatment of Covid-19 on Carbonic Anhydrase I-II Isoenzymes and Acetylcholine Enzyme Activities in Vitro


Creative Commons License

Arık S., KOÇYİĞİT Ü. M.

Cumhuriyet Science Journal, cilt.44, sa.1, ss.67-71, 2023 (Hakemli Dergi) identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 44 Sayı: 1
  • Basım Tarihi: 2023
  • Doi Numarası: 10.17776/csj.1134711
  • Dergi Adı: Cumhuriyet Science Journal
  • Derginin Tarandığı İndeksler: TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.67-71
  • Sivas Cumhuriyet Üniversitesi Adresli: Evet

Özet

Covid-19, originating from Wuhan, China, is a worldwide health problem. Immune system abnormalities caused by covid-19 lead to infections, septic shock, and severe multi-organ dysfunction. The drugs used for treatment are palliative pharmacological alternatives and help manage symptoms or complications that occur during the course of the disease. Both carbonic anhydrases and cholinesterases can be target enzymes for drugs. The goal of this study is to determine how the drugs used in covid-19 affect patients being treated for Alzheimer's disease, myasthenia gravis, glaucoma, or epilepsy, and to determine if there are drug-drug interactions. In case of possible interactions, it is crucial for these patients to consider alternative treatments and to recheck the dosage of the drugs used. To this end, the effects of the drugs favipiravir and oseltamivir, which are used in the covid-19 clinic and whose relationship with these enzymes has not been previously studied, on the isoenzymes of carbonic anhydrase I- II and the enzyme acetylcholinesterase were studied in vitro. No inhibition or activation was observed on the enzyme acetylcholinesterase, while inhibition was observed for the isoenzyme carbonic anhydrase I - II.